Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Rousseau C, et al. Among authors: chatal jf. J Clin Oncol. 2006 Dec 1;24(34):5366-72. doi: 10.1200/JCO.2006.05.7406. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088570 Clinical Trial.
Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans.
Rousseau C, Bourbouloux E, Campion L, Fleury N, Bridji B, Chatal JF, Resche I, Campone M. Rousseau C, et al. Among authors: chatal jf. Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):785-91. doi: 10.1007/s00259-006-0066-x. Epub 2006 Apr 5. Eur J Nucl Med Mol Imaging. 2006. PMID: 16596378 Clinical Trial.
Nuclear medicine applications for neuroendocrine tumors.
Chatal JF, Le Bodic MF, Kraeber-Bodéré F, Rousseau C, Resche I. Chatal JF, et al. World J Surg. 2000 Nov;24(11):1285-9. doi: 10.1007/s002680010213. World J Surg. 2000. PMID: 11038195 Review.
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: chatal jf. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3973S-81S. Clin Cancer Res. 2003. PMID: 14506196 Clinical Trial.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: chatal jf. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
206 results